Editas Medicine, Inc. reports results for the quarter ended September 30 - Earnings Summary

• Editas Medicine, Inc. reported a quarterly adjusted loss of 15 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -28 cents. The mean expectation of twelve analysts for the quarter was for a loss of 19 cents per share. Wall Street expected results to range from -25 cents to -13 cents per share.

• Revenue rose 37.4% to $10.37 million from a year ago; analysts expected $4.46 million.

• Editas Medicine, Inc.'s reported EPS for the quarter was a loss of 15 cents​.

• The company reported a quarterly loss of $23.39 million.

• Editas Medicine, Inc. shares had held steady so far this quarter and gained 25.4% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 3.9% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," 2 "hold" and 2 "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Editas Medicine, Inc. is $5.50, about 53.3% above its last closing price of $2.57

This summary was machine generated from LSEG data November 9 at 02:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)